Last reviewed · How we verify

Aripiprazole tablets — Competitive Intelligence Brief

Aripiprazole tablets (Aripiprazole tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry / Neurology.

phase 3 Atypical antipsychotic Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (partial agonist); Serotonin 5-HT2A receptor (antagonist) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Aripiprazole tablets (Aripiprazole tablets) — Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors, which stabilizes dopamine and serotonin neurotransmission in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aripiprazole tablets TARGET Aripiprazole tablets Chengdu Kanghong Pharmaceutical Group Co., Ltd. phase 3 Atypical antipsychotic Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (partial agonist); Serotonin 5-HT2A receptor (antagonist)
Lybalvi SAMIDORPHAN Alkermes Inc marketed Atypical Antipsychotic [EPC] Mu-type opioid receptor 2021-01-01
SAMIDORPHAN L-MALATE SAMIDORPHAN L-MALATE marketed Atypical Antipsychotic [EPC] dopamine and serotonin type 2 (5HT2) receptors, opioid receptors 2021-01-01
Caplyta LUMATEPERONE Intra-Cellular marketed Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2A 2019-01-01
Nuplazid PIMAVANSERIN Acadia Pharms Inc marketed Atypical Antipsychotic 5-hydroxytryptamine receptor 2A 2016-01-01
Vraylar CARIPRAZINE AbbVie marketed Atypical Antipsychotic [EPC] D(3) dopamine receptor 2015-01-01
Rexulti BREXPIPRAZOLE Otsuka marketed Atypical Antipsychotic [EPC] D(2) dopamine receptor 2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Atypical antipsychotic class)

  1. Shanghai Mental Health Center · 10 drugs in this class
  2. AstraZeneca · 6 drugs in this class
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
  5. Eli Lilly and Company · 4 drugs in this class
  6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
  7. Medical University of Vienna · 2 drugs in this class
  8. Organon and Co · 2 drugs in this class
  9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  10. H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aripiprazole tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/aripiprazole-tablets. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: